Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

163.10 +1.92 (+1.19%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

41 42 Next >

Novartis Reveals Long-Term Data Of Atrophy Gene Therapy Exhibiting Sustained Durability Of Up To 7.5 Years ↗

March 20, 2023

Via Benzinga

FDA Approves Novartis' Tafinlar + Mekinist For Pediatric Brain Cancer With Certain Mutations ↗

March 17, 2023

Via Benzinga

Elon Musk Frets As Microsoft Axes AI Ethics Team, Richard Branson's Virgin Orbit Stops Ops, Credit Suisse To Borrow Up To $54B: Today's Top Stories ↗

March 16, 2023

Benzinga

Via Benzinga

Novartis' Prostate Cancer Therapy Hit By Supply Crunch, Seeks To Ramp Up Production To Ease Supply Issues ↗

March 16, 2023

Last week the FDA said Novartis AG's (NYSE: NVS) Pluvicto is short in supply due to manufacturing and delivery issues. Pluvicto is a radiopharmaceutical medication used for prostate-specific membrane...

Via Benzinga

3 High Dividend Stocks With Attractive Total Return Potential ↗

March 10, 2023

In the current economic environment, it is crucial for investors to prioritize quality, reliable dividend stocks and high total returns.

Via InvestorPlace

This High-Yielding Blue Chip Stock Is a Strong Buy ↗

February 13, 2023

This big pharma company pays a market-topping dividend to shareholders.

Via The Motley Fool

Top CRISPR Stocks ↗

February 11, 2023

CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.

Via Talk Markets

Novartis Ag (NVS) Q4 2022 Earnings Call Transcript ↗

February 01, 2023

NVS earnings call for the period ending December 31, 2022.

Via The Motley Fool

Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?

March 08, 2023

Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?

Via News Direct

Topics Economy

Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? ↗

March 07, 2023

Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics.

Via Benzinga

4 AI Stocks That Are Revolutionizing Healthcare ↗

March 06, 2023

With the growing use of AI in healthcare, it has led to a number of stocks that are focused on this industry.

Via InvestorPlace

This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier? ↗

March 03, 2023

Texas-based biotech company, Coya Therapeutics (NASDAQ: COYA), is positioning itself as a leader in a promising area of the medical field.

Via Benzinga

Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off ↗

February 01, 2023

Via Benzinga

A Preview Of Novartis's Earnings ↗

January 31, 2023

Via Benzinga

Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca ↗

February 25, 2023

Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...

Via Talk Markets

Novartis Takes Down $80M NASH Pact With Pliant Therapeutics ↗

February 24, 2023

Via Benzinga

Better Buy: Beam Therapeutics or Intellia Therapeutics? ↗

February 22, 2023

The two clinical-stage gene-editing companies have good long-term prospects.

Via The Motley Fool

Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path ↗

February 14, 2023

Via Benzinga

Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review ↗

February 03, 2023

The major indexes continued to run despite mixed-to-weak earnings.

Via Investor's Business Daily

Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric ↗

February 02, 2023

The company that remains still has a large pipeline of non-migraine assets.

Via Investor's Business Daily

Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line? ↗

February 02, 2023

The index futures point to a mixed opening on Thursday, as tech earnings continue to be encouraging.

Via Benzinga

Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report ↗

February 01, 2023

Two of the three companies easily beat sales and earnings expectations, but sales fell for the third.

Via Investor's Business Daily

US Stocks On Track For Nervous Start As Traders Go Fed Watching: AMD Earnings Calm Investors ↗

February 01, 2023

Futures trading point to a negative start by Wall Street stocks on Wednesday as traders exercise restraint ahead of the Fed decision due in the afternoon. Cues From Tuesday’s Trading:

Via Benzinga

Earnings Scheduled For February 1, 2023 ↗

February 01, 2023

Companies Reporting Before The Bell • Novo Nordisk (NYSE:NVO) is expected to report quarterly earnings at $0.85 per share on revenue of $6.84 billion.

Via Benzinga

7 CRISPR Stocks With the Best Long-Term Potential ↗

January 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Via InvestorPlace

Philips Reports Q4 Earnings, To Lay Off Additional Employees This Year, Shares Jump ↗

January 30, 2023

Koninklijke Philips NV (NYSE: PHG) would reduce its workforce by an additional 6,000 roles globally by 2025, of which 3,000 will be implemented in 2023 to restore its profitability following a recall...

Via Benzinga

Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch ↗

January 29, 2023

With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.

Via Benzinga

Could This Be Novartis' Next Blockbuster Medicine? ↗

January 27, 2023

The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.

Via The Motley Fool

Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering ↗

January 24, 2023

Via Benzinga

3 Drug Stocks With Promising Pipelines for 2023 ↗

January 23, 2023

These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors.

Via InvestorPlace

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

Headline News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today